Using Cannabis to Treat Cancer-Related Pain
Section snippets
Cannabinoids and Pain
In 2016, The American Society of Clinical Oncology published guidelines to help cancer survivors manage chronic pain. These recommendations included the use of cannabis and cannabinoid-based medicines.7 The National Academy of Sciences, in their 2017 report titled The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, stated that “There is conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment
Cannabinoids and Terpenes as Analgesic Agents
A cannabinoid is a chemical compound that influences cannabinoid receptors in cells to affect neurotransmitter release. The term cannabinoid can refer to any of the following categories—phytocannabinoids, endocannabinoids, and synthetic cannabinoids10., 11.:
- •
Endocannabinoids are cannabinoids produced by and found in the nervous systems and in the immune systems of humans and animals. The two most well understood of these molecules are called anandamide (AEA) and 2-arachidonoylglycerol (2-AG).
Cannabinoids and Opioid Requirements
Cannabis can be a helpful analgesic adjuvant in patients with cancer. Patients with chronic pain have realized relief from cannabinoids in both inflammatory42 and neuropathic pain,43 among other pain categories. In three case studies presented by the Queen Elizabeth II Health Sciences Center in Nova Scotia, Canada, patients who supplemented with cannabis either reduced or eliminated their opioid requirements.44 Also, in a randomized, placebo-controlled, double-blinded crossover study, when THC
Using Cannabinoids to Treat Nociceptive Pain
Data suggest that cannabis can be effective at treating nociceptive pain when the pain has a maintaining cause. For example, a randomized, double-blind, placebo-controlled crossover trial using a 1:1 oromucosal spray in a group of 17 patients suffering from multiple sclerosis-based nociceptive pain found that cannabinoids provided relief to these patients.49 In another study, researchers found that CB1 receptors, CB2 receptors, and anandamide were abundant in the affected tissue of 45 patients
Using Cannabinoids to Treat Neuropathic Pain
Neuropathic pain is one of the most challenging pain syndromes to treat in patients with cancer. The pain can be centrally mediated (for example, brachial plexopathy resulting from a Pancoast tumor) or peripherally mediated (for example, chemotherapy-induced peripheral neuropathy [CIPN]). Nearly 40% of cancer pain is a result of peripheral neuropathy (PN) and studies have suggested that PN pain is more difficult to control with conventional therapies. CIPN is a predictor of PN and patients
Using Cannabinoids to Treat Nociplastic Pain
Data suggest the ECS, which is pivotal in mammalian nociception, is activated under stressful conditions,82 and can be an important signaling pathway for immune modulation.83 There is growing evidence84 that the ECS might be involved in modulating nociplastic pain as well. Nociplastic pain is a general category for all types of pain that do not fit into the nociceptive or neuropathic pain categories.85 Fibromyalgia, non-specific low back pain, and irritable bowel syndrome are all examples of
Assessment
Patient assessment in cannabis therapeutics leverages many of the same evaluation techniques from traditional modalities designed to reveal dysfunction and disease. Cannabis health care professionals should review the following patient information before the appointment:
- •
Medical records related to the illness or condition;
- •
Results of all related tests or examinations;
- •
A list of medications and supplements, including indications, dates, type, dosage, and quantity prescribed;
- •
A list of all allergies
Administration for Cancer Pain
There are a number of different delivery methods that patients with cancer can use to consume cannabis. Absorption, efficacy, and side effects are influenced by each method of administration. Typically, patients can benefit by using multiple different routes of administration when managing pain.
Dosing
Dosing remains one the biggest challenges to cannabis administration. There exist no standard cannabis dosing guidelines, no established safety standards, and a patient's response will vary. Cannabis dosing poses unique complexities because of unregulated markets, where there remain poorly labeled products and products with little quality assurance. Patients in most medical states lack opportunities to discuss cannabis products with a pharmacist, and therefore might not be informed about issues
Cancer Patient Case Study: Peripheral Neuropathy
A.Y. is a 53-year-old woman diagnosed with stage IIIB stomach cancer. Her chemotherapy regimen included FLOT (docetaxel, oxaliplatin, fluorouracil/leucovorin, oxaliplatin, and docetaxel) every 3 weeks for eight cycles. Midway through her chemotherapy regimen she developed CIPN grade 3, as defined by the National Cancer Institute Common Toxicity Criteria.96 A.Y. reported that she could not feel her feet. Her balance was unstable (though she suffered from no falls). The tingling sensations in her
Product Safety Considerations
Health care professionals should assist patients in making an informed decision for purchasing safe cannabis products. First, health care professionals should advise patients to purchase products only through state-regulated and county-licensed dispensaries and to avoid non-licensed dispensaries or delivery services. Patients can check their state, county, and department Web sites to locate a licensed dispensary or delivery service. Second, patients should call or visit dispensaries and ask if
Conclusion
Cannabis and cannabinoid medicines, as modulators of the ECS, can offer novel therapeutic options for the treatment of cancer-related pain, not only for patients who do not respond to conventional therapies, but also for patients who prefer to try cannabis (because of its safety profile, the relatively mild side effects, and high tolerability) as a first treatment option. While evidence for the use of cannabis is building, more research is needed in patients with cancer. Randomized controlled
References (97)
Cannabinoid receptors and pain
Prog Neurobiol
(2001)- et al.
Cannabis pharmacology: the usual suspects and a few promising leads
Adv Pharmacol
(2017) - et al.
Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression
Eur J Pharmacol
(1987) - et al.
Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice
Psychoneuroendocrinology
(2002) - et al.
Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea
J Ethnopharmacol
(2007) - et al.
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
Biochem Pharmacol
(2013) - et al.
Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms
Neuropharmacology
(2012) - et al.
Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist
Neuroscience
(1996) - et al.
The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
Neurosci Lett
(1997) - et al.
Cannabis reduces opioid dose in the treatment of chronic non-cancer pain
J Pain Symptom Manage
(2003)
Cannabinoids modulate pain by multiple mechanisms of action
J Pain
Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain
J Pain
Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis
Eur J Pain
A case of cannabinoid rotation in a young woman with chronic cystitis
J Pain Symptom Manage
Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats
Int Immunopharmacol
Are oral cannabinoids safe and effective in refractory neuropathic pain?
Eur J Pain
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial
Pain
Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial
Pain
Cannabinoids and cancer pain: a new hope or a false dawn?
Eur J Intern Med
Low-dose vaporized cannabis significantly improves neuropathic pain
J Pain
Allodynia lowering induced by cannabinoids and endocannabinoids (ALICE)
Pharmacol Res
In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation
Int J Pharm
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model
J Control Release
Cannabis epidemiology: a selective review
Curr Pharm Des
Smoking, vaping, and use of edibles and other forms of marijuana among U.S. Adults
Ann Intern Med
Part I: current legislation, scientific literature review, and nursing implications
J Nurs Reg
Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use
Cancer
Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline
J Clin Oncol
The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research
Chronic and refractory pain: a systematic review of pharmacologic management in oncology
Clin J Oncol Nurs
Phytocannabinoids beyond the Cannabis plant - do they exist
Br J Pharmacol
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
Br J Pharmacol
Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review
JAMA
The biodisposition and metabolism of anandamide in mice
J Pharmacol Exp Ther
TRPV1: on the road to pain relief
Curr Mol Pharmacol
5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats
Br J Pharmacol
Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stresses in rabbits
Am J Physiol Regul Integr Comp Physiol
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors
Naunyn Schmiedebergs Arch Pharmacol
Cannabidiol: a promising drug for neurodegenerative disorders?
CNS Neurosci Ther
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors
Nat Neurosci
Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain
Mol Neurobiol
CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents
J Neurosci
Ingestion of cinnamaldehyde, a TRPA1 agonist, reduces visceral fats in mice fed a high-fat and high-sucrose diet
J Neurti Sci Vitaminol (Tokyo)
Affinity and efficacy studies of tetrahydrocannabinolic acid a at cannabinoid receptor types one and two
Cannabis Cannabinoid Res
Cited by (12)
-
Perspectives of Complementary and Alternative Medicine use by cancer patients in a regional hospital in North Queensland, Australia
2022, Complementary Therapies in MedicineCitation Excerpt :The use of cannabis as a complementary therapy with conventional cancer treatment could provide some complications in an oncology care setting. There are various anecdotal indications for cannabis for oncology patients, including treating chemotherapy-induced nausea and vomiting, depression, insomnia, anorexia, and cancer-related pain, as well as suggested anti-cancer properties.29–32 However, much of the evidence for these indications is considered of low quality, with a recent review suggesting that sufficient evidence is only in support of add-on therapy for nausea and vomiting and refractory pain in a palliative setting.32
-
Validation of a high-throughput method for analysis of pesticide residues in hemp and hemp products
2021, Journal of Chromatography ACitation Excerpt :More than 550 different compounds have been identified in this plant, including 90 phytocannabinoids (e.g. THC, cannabidiol), more than 100 terpenes, about 20 phenolic compounds (e.g. flavonoids), and a large amount of proteins, hydrocarbons, sugars, fatty acids, carotenes, and phytosterols, among others [11,12]. Some of these components, like cannabinoids and terpenes, are present in the plant at 0.2–2% [13] and 1–10% [14], respectively. These chemicals at such high concentrations cause analytical problems since they are co-extracted with trace level pesticides by organic solvents and may directly and/or indirectly interfere in the analysis.
-
Towards the Microbial Production of Plant-Derived Anticancer Drugs
2020, Trends in CancerCitation Excerpt :However, the use of these compounds by cancer patients is currently booming due to their capacity to reduce pain caused by cancer and/or chemotherapy. In addition, these cannabinoids have been approved as antiemetics, anticachexics, analgesics, or antispastic medicines by several regulatory agencies [12]. However, cannabinoid synthesis in hemp can be highly variable in planta and the complex structures limit chemical synthesis approaches, thus requiring the development of complementary processes of supply to meet the demand.
-
Proteomic Changes in Methicillin-Resistant Staphylococcus aureus Exposed to Cannabinoids
2023, Journal of Natural Products -
Current Cannabidiol Safety: A Review
2023, Current Drug Safety